All In Biotech

Drug Trial Radar · NCT06440525

A Study of RSLV-132 in Females With Sjögren's Disease

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Sjögren's Disease With Moderate to Severe Symptom Burden

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Dec 1, 2024

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
Resolve TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device

Conditions

  • Primary Sjögren Syndrome

Interventions

  • RSLV-132Drug

    Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)

  • PlaceboDrug

    0.9% sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of cardinal symptoms of Sjogren'sTime frame: Measured daily from at least 7 days prior to first dose until 169 days after the first dose

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Resolve Clinical Site

    Chula Vista, California

  • Resolve Clinical Site

    Tustin, California

  • Resolve Clinical Site

    Boca Raton, Florida

  • Resolve Clinical Site

    Boynton Beach, Florida

  • Evolution Research Center

    Hialeah, Florida

  • GNP Research

    Hollywood, Florida

  • Resolve Clinical Site

    Miami, Florida

  • Life Medical Research

    Miami Gardens, Florida

  • Resolve Clinical Site

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Tufts College

    Boston, Massachusetts

  • Resolve Clinical Site

    Albuquerque, New Mexico

  • Joint and Muscle Research Institute

    Charlotte, North Carolina

  • Arthritis and Osteoporosis Consultants of the Carolinas

    Charlotte, North Carolina

  • Onsite Clinical Solutions

    Salisbury, North Carolina

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Resolve Clinical Site

    Nashville, Tennessee

  • Resolve Clinical Site

    Austin, Texas

  • Resolve Clinical Site

    Katy, Texas

  • Resolve Clinical Site

    McKinney, Texas

  • Accurate Clinical Research

    Richmond, Texas

  • Resolve Clinical Site

    San Antonio, Texas

  • Metrodora Institute

    Salt Lake City, Utah

  • Arthritis Northwest

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.